ZHANG LEI,SUBRAMANYAM CHAKRAPANI,DAVOREN JENNIFER E.,DOUNAY AMY BETH,EFREMOV IVAN V,GRAY DAVID L.F.,MENTE SCOT R.,O'NEIL STEVEN V.,ROGERS RUCE N.
申请号：
CL2015001233
公开号：
CL2015001233A1
申请日:
2015.05.07
申请国别(地区):
CL
年份:
2015
代理人:
摘要：
The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof and N-oxides of the foregoing； processes for the preparation of； intermediates used in the preparation of； and compositions containing such compounds, salts or N-oxides, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, impulsivity, compulsive gambling, overeating, autism spectrum disorder, MCI, age-related cognitive decline, dementia, RLS, Parkinson's disease, Huntington's chorea, anxiety, depression, MDD, TRD, and bipolar disorder.<；p>；LA SOLICITUD SE REFIERE A COMPUESTOS DERIVADOS DE PIRROLOPIRIDINA Ó； PIRAZOLOPIRIDINA, AGONISTA O AGONISTAS PARCIALES D1, A UNA COMPOSICIÓ；N FARMACÉ；UTICA QUE LOS COMPRENDE Y A SU USO EN EL TRATAMIENTO ENFERMEDADES DEL SNC, CARDIOVASCULARES, ENTRE OTRAS<；/p>；
